Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02810444 · ClinicalTrials.gov registry record · Phase 3
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
A Phase 3 study, sponsored by Biotest.
- Completed
- Registry status
- Phase 3
- Development phase
- 81
- Enrollment target
NCT02810444 is a Phase 3 study that has completed, run by Biotest. The registered enrollment target is 81 participants.
The verdict
NCT02810444, a Phase 3 study, has completed, sponsored by Biotest.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 81 participants
- Enrollment target
Study Summary
This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
Interventions
- BIOLOGICAL IgG Next Generation (BT595)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-10-04 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02810444
The ClinicalTrials.gov registry entry for NCT02810444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotest, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IgG Next Generation (BT595) is the first listed.
NCT02810444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02810444 about?
NCT02810444 is a clinical study titled "Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID". This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
What is the current status of trial NCT02810444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 81 participants. The study started on 2016-10-04. Estimated completion is 2020-04-01.
What interventions are being tested in trial NCT02810444?
The interventions under investigation include: IgG Next Generation (BT595) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02810444?
This trial is sponsored by Biotest, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.